Bone Marrow Aspirate Concentrate for Anterior Cruciate Ligament Tear Treatment.

Launched by ABDULMAJEED HAMMADI · Apr 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for people who have torn their anterior cruciate ligament (ACL), which is a common injury, especially for athletes. The study is testing the use of a special treatment called bone marrow aspirate concentrate (BMAC). This involves taking a small amount of bone marrow from the patient’s body, concentrating it, and then injecting it back into the knee to help with healing. The trial is currently enrolling participants and will involve around 20 patients, who will receive this treatment under local or general anesthesia.

To be eligible for the trial, participants need to be between 20 and 55 years old and must have a diagnosed complete or partial ACL tear. However, individuals with certain health conditions, like bleeding disorders or a history of cancer, cannot participate due to safety concerns. Those who join the trial can expect to receive the BMAC treatment in a sterile environment while being monitored closely. This trial aims to determine how effective this treatment is in helping people recover from ACL injuries, which can be a significant concern for active individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1- Confirmed diagnosis of complete or partial ACL tear via clinical examination and imaging studies.
• • 2. Aged between 20 and 55 years, to encompass the typical age range of patients with sports-related ACL injuries.
• Exclusion Criteria:
• • 1- Patients with a history of bleeding disorders, as this could complicate the aspiration and injection procedures.
• • 2. Individuals with a history of malignancy, due to the potential risks associated with growth factors present in BMAC.
• • 3. Critically ill patients or those with comorbidities